Each one in plain English, with the numbers worked through for a shareholder.
12 June 2025capital raising announcement● Neutral
The share purchase plan raised only A$335,000 from 3,045,436 shares at A$0.11, far below the up to A$4M offered. Shares were issued without using placement capacity.
What it means for a shareholder
3.0m new shares at A$0.110 to raise about A$335,000. Shares on issue before the raise aren't in the record, so the dilution can't be worked out.
Reminder that the share purchase plan closes 6 June 2025 at A$0.11, up to A$30,000 per holder, with instructions on applying via Automic. No new information.
May 2025 investor presentation on Hombre Muerto West. Visible text is disclaimers and competent person statements, with no new figures; it appears to restate known project information.
Re-release of the May investor presentation; the only change is page 7, which now states the nano-filtration plant at HMW is expected to be commissioned in H2 2025. Administrative.
The share purchase plan closing date is extended from 22 May to 6 June 2025, citing mailing delays and alignment with the 5 June general meeting. Price stays A$0.11, max A$30,000 per holder; allotment moves to 12 June.
Offer booklet for the share purchase plan at the A$0.11 placement price (per the 16 April announcement): eligible holders may buy up to A$30,000 of shares, closing 23 May 2025, with allotment on 29 May. The SPP was announced as up to A$4M.
Secondary trading notice for 99,832,755 shares issued on 28 April 2025 under the 16 April placement. Administrative only; confirms the first tranche of the A$0.11 placement.
Galan signs binding offtake and operating agreements with Authium: 45kt LCE over 6-12 years, US$6M prepayments, and Authium funds the HMW processing plant, removing A$41.5M capex. A ~A$13M placement at A$0.11 plus up to A$4M SPP follows. Replaces Chemphys MOU; first production still H1 2026.
Capital raising presentation titled 'Funding and Offtake Secured', supporting the April Authium agreements and placement. The visible text is disclaimers; it appears to repeat the announcement made the same day.
Galan requested a voluntary trading suspension from 14 April 2025, pending a definitive offtake agreement and capital raise announcement. It was due to last until 16 April at most. Signals a funding deal is close.
Galan answers an ASX query on why the rejected Huayou/Renault proposal was first disclosed in the 3 April notice. Received 30 March, rejected 3 April; it relied on the confidential incomplete-proposal exception and confirmed Listing Rule compliance.
Routine secondary trading notice for 5.7M ATM shares, but it discloses that Galan rejected an unsolicited non-binding US$150M cash proposal from Huayou Cobalt and Renault for HMW and Candelas. The board called it opportunistic and undervaluing, citing near-term offtake and financing.
Eighth Acuity at-the-market draw: A$575k from 5.7M shares at A$0.101, an 8.2% discount to the 15-day VWAP, for working capital. A small draw at a lower price than February's A$0.115.
What it means for a shareholder
5.7m new shares at A$0.101 to raise about A$575,000. Shares on issue before the raise aren't in the record, so the dilution can't be worked out.
Half-year to 31 December 2024: loss A$5.54M (A$4.55M a year earlier), cash A$3.6M (A$4.3M at June). Focus remains on HMW Phase 1 and funding; the visible text shows no new developments beyond known issues.
S&P Dow Jones March 2025 index rebalance notice, a market-wide list of changes. It is not a Galan announcement; the visible list shows Galan removed from the All Ordinaries from 24 March 2025.
Seventh Acuity at-the-market draw: A$1.5M from 13M shares at A$0.115, a 0.5% discount to the 15-day VWAP, for working capital. Priced below the A$0.12 draw in December 2024.
What it means for a shareholder
13.0m new shares at A$0.115 to raise about A$1.5m. Shares on issue before the raise aren't in the record, so the dilution can't be worked out.
Secondary trading notice for the 13,000,000 shares issued on 28 February 2025 under the Acuity at-the-market deed. Administrative only; repeats the draw announced the same day.
Presentation to the RIU Explorers conference in February 2025. It appears to repeat known Hombre Muerto West material, including the January 2025 resource update; the visible text shows no new announcement.
December quarter: about 7,900t LCE in ponds, cash A$3.6M, Chemphys US$3M received. First Phase 1 production is now targeted for H1 2026, later than the H2 2025 target, with timing adjusted for financing and offtake talks. Prepayment facility still targets Q1 2025 close.
Secondary trading notice for 42,835,724 shares issued on 30 January 2025 under a placement. Administrative only; the text gives no price or buyer. It may relate to the Chemphys placement (inference).
Candelas resource grows more than 150% to 1.6Mt LCE (from 685kt in 2019), lifting Galan's total to 9.5Mt LCE. HMW is unchanged at 7.9Mt, which differs from the 8.6Mt total booked in March 2024. Galan says it ranks in the global top 10.
28 Jan 2025capital raising announcement▲ GoodMajor
Galan received the US$3M Chemphys placement money via affiliate Latam Resources, after shareholders approved it at the 15 November 2024 AGM. Funds go to Phase 1 work. The offtake prepayment facility is still unsigned, targeting close in Q1 2025.
Replacement of the 6 January Phase 2 permit announcement, with a corrected Wood Mackenzie cost curve chart, an expanded footer and an ASX Listing Rule 5.19 statement. No change to the permit news.
Catamarca granted the full Phase 2 mining permit for up to 21,000tpa LCE at HMW, a permit Galan had been pursuing. Expansion still needs project finance and Phase 1 delivery. The company says Phase 2 would be cash flow positive at current prices.
Sixth Acuity at-the-market draw: A$1.8M from 15M shares at A$0.12, equal to the 15-day VWAP, for working capital. The price is above the August A$0.1222 draw but far below the A$0.283 of the first draw in May.
What it means for a shareholder
15.0m new shares at A$0.120 to raise about A$1.8m. Shares on issue before the raise aren't in the record, so the dilution can't be worked out.